Carregando empresa
Just reported
Q3 2026 results
From Editas Medicine's results release of 9 de novembro de 2026; its quarterly report has since been filed.
Revenue
Actual
US$ 10,4M
+37% y/y
-13% q/qGuided
—
No guide given
EPS, GAAP
Actual
-US$ 0,15
Guided
—
No guide given
Operating income, GAAP
Actual
-US$ 24,3M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Editas Medicine is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.US$ 48BA+
EXELExelixis, Inc.US$ 17,3BA+
JAZZJazz Pharmaceuticals plcUS$ 15,9BA
HALOHalozyme Therapeutics, Inc.US$ 11,6BA+
TECHBIO-Techne CorpUS$ 11,4BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 de out. de 2026CBGraded C, now B
MCKMckesson Corporation4 de nov. de 2026BAGraded B, now A
CVSCVS Health Corp4 de nov. de 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 de nov. de 2026BAGraded B, now A
BIIBBiogen Inc.28 de out. de 2026BAGraded B, now A
Como ganha dinheiro
- Licensing and research collaborations100%
As participações na receita são estimativas para FY2025, não números de um relatório oficial.
Concorre com
- CRSPCRISPR TherapeuticsF
- Tamanho
- US$ 4,5B
- Margem
- -1.812,1%
- BEAMBeam TherapeuticsF
- Tamanho
- US$ 2,7B
- Margem
- -73,9%
- NTLAIntellia TherapeuticsD
- Tamanho
- US$ 1,6B
- Margem
- -805,7%
- VRTXVertex PharmaceuticalsB
- Tamanho
- US$ 138,7B
- Margem
- 30,7%
- AMGNAmgenA
- Tamanho
- US$ 253,2B
- Margem
- 24,1%
- REGNRegeneron PharmaceuticalsC
- Tamanho
- US$ 101,3B
- Margem
- 28,5%
O que vende3
EDIT-401
An experimental one-time treatment designed to edit liver cells so they produce more of a protein that removes LDL cholesterol from the blood. It was being prepared for a Phase 1/2 human trial in people with inherited high cholesterol.
In-vivo blood stem-cell editing program
A research program intended to edit blood-forming stem cells inside the body to raise fetal hemoglobin, with the aim of treating sickle cell disease and transfusion-dependent beta thalassemia.
Cas9 and Cas12a gene-editing technology
Gene-editing tools that Editas licenses to partners for research and development of medicines, including treatments that modify immune cells.
Quem compra3
- Bristol Myers Squibb: collaborates on research into gene-edited immune-cell treatments and may make milestone and royalty payments.
- Vertex Pharmaceuticals: licenses Editas gene-editing technology for medicines targeting inherited blood disorders and pays annual license fees.
- Immatics: collaborates with Editas on gene-edited immune-cell treatments for cancer.
Em que se apoia e o que pode quebrá-lo
Do que o negócio depende
- 1The business depends heavily on EDIT-401, its lead medicine, and on advancing it from preclinical research into human trials.
- 2Editas licenses important gene-editing patents from universities and research institutions; those agreements require payments and compliance with their terms.
- 3It relies on outside manufacturers and service providers for research materials and planned clinical trials, and on partners and investors for funding.
O que pode dar errado
- 1EDIT-401 has not yet established safety or effectiveness in people; failure or delay in its development could significantly affect the business.
- 2Gene-editing patents and licenses are subject to disputes and challenges, which could limit Editas's rights to use or license important technology.
- 3Editas has no medicine-sale revenue and needs substantial funding; if it cannot raise money or receive partner payments, it may have to cut or delay research and development.
Demonstrações financeiras completas →
Sobre a Editas Medicine, Inc.
Editas develops medicines that change deoxyribonucleic acid (DNA) to treat disease. Its CRISPR (clustered regularly interspaced short palindromic repeats) technology uses a guide molecule to direct an enzyme to a chosen DNA location. Its lead medicine, EDIT-401, is being prepared for early human testing to lower low-density lipoprotein (LDL) cholesterol; the company also licenses its technology and works with drug companies on research programs.
- Sede
- Cambridge, Massachusetts
- Fundada em
- 2013
- Listada em
- Nasdaq
- Fim do exercício
- December 31
Construído a partir dos próprios documentos de Editas Medicine, Inc. entregues à Comissão de Valores Mobiliários dos EUA (SEC). Os números são os divulgados, com o histórico por ação recalculado para a base de ações de hoje. Isto descreve um negócio — não é recomendação de investimento nem sugestão de compra ou venda.
